We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Authors
Moreau, Philippe; Chari, Ajai; Oriol, Albert; Martinez-Lopez, Joaquin; Haenel, Mathias; Touzeau, Cyrille; Ailawadhi, Sikander; Besemer, Britta; de la Rubia Comos, Javier; Encinas, Cristina; Mateos, Maria-Victoria; Salwender, Hans; Rodriguez-Otero, Paula; Hulin, Cyrille; Karlin, Lionel; Sureda Balari, Anna; Bargay, Joan; Benboubker, Lotfi; Rosiñol, Laura; Tarantolo, Stefano
- Abstract
Patients in PLEIADES and EQUULEUS had received a median (range) of 1 (1-1) and 2 (1-4) prior lines of therapy, respectively, and 60 (90.9%) and 85 (100%) patients had received prior proteasome inhibitor therapy. EQUULEUS (NCT01998971) evaluated daratumumab IV plus weekly Kd (carfilzomib 70 mg/m SP 2 sp ; dexamethasone 40 mg) in RRMM patients after 1 to 3 prior lines of therapy (including bortezomib and an immunomodulatory drug). Patients in CANDOR received carfilzomib 56 mg/m SP 2 sp twice weekly (monthly cumulative dose, 336 mg/m SP 2 sp [Cycle 1, 264 mg/m SP 2 sp ]), while patients in PLEIADES and EQUULEUS received carfilzomib 70 mg/m SP 2 sp weekly (monthly cumulative dose, 210 mg/m SP 2 sp [Cycle 1, 160 mg/m SP 2 sp ]; ie, 62.5% of CANDOR monthly dose).
- Subjects
DARATUMUMAB; PLEIADES; MULTIPLE myeloma; HEART failure
- Publication
Blood Cancer Journal, 2023, Vol 13, Issue 1, p1
- ISSN
2044-5385
- Publication type
Article
- DOI
10.1038/s41408-023-00805-x